This week in therapeutics




Licensing status

Publication and contact information



V-set domain containing T cell activation inhibitor 1 (VTCN1; B7-H4)

Studies in vitro, in mice and in patient samples identified anti-B7-H4 single-chain variable antibody fragments (scFvs) that could help treat cancer. In ovarian cancer samples from
15 patients, B7-H4 was expressed on the surface of all samples. A screen in yeast identified scFvs that bound B7-H4, and these scFvs reversed B7-H4-mediated inhibition of donor T cell activation. In a humanized mouse model for ovarian cancer, scFvs against
B7-H4 reduced tumor growth. Next steps could include testing anti-B7-H4 scFvs or antibodies in additional ovarian cancer models.

SciBX 6(27); doi:10.1038/scibx.2013.680
Published online July 18, 2013

Patent and licensing status unavailable

Dangaj, D. et al. Cancer Res.; published online May 30, 2013;
Contact: Nathalie Scholler, SRI International, Menlo Park, Calif.